Navigation Links
Medical whistleblowers speak out

The US Food and Drug Administration (FDA) was "the single greatest obstacle to doing anything effective" about Vioxx, said FDA drug safety officer David Graham at an unprecedented roundtable of medical whistleblowers sponsored by the Public Library of Science (PLoS) and the Government Accountability Project.

In comments that echoed his now infamous testimony to the US Senate Finance Committee, Graham said that, "Nearly 60,000 people probably died from that drug. That's as many of our soldiers that were killed in the Vietnam war [who] died as a result of Vioxx use. And FDA had the opportunity, the responsibility, to stop that and didn't."

Graham was one of five high profile medical whistleblowers invited by the medical investigative journalist Jeanne Lenzer to meet together in Washington DC on May 15th 2005 to share their accounts of practices in medicine and medical research that they believe are risking the public's health or safety. Lenzer's account of the roundtable, in which she outlines the lessons we can learn from these whistleblowers, is published in the open access international medical journal PLoS Medicine. One of the lessons, says Lenzer, is that "ties between drug regulators and industry may influence new drug approval." Graham said at the roundtable that the FDA was in "a collaborative relationship" with industry, and that the FDA gets money from drug companies through the Prescription Drug User Fee Act "to approve new drugs and approve them more quickly." A senior official at the FDA, said Graham, had told him, "industry is our client."

"The pharma-FDA complex has to be dismantled," he said, "and the American people have to insist on that, otherwise we're going to have disasters like Vioxx that happen in the future."

Another lesson, says Lenzer, is that "the race to approve new drugs without proper safety testing may be compromising the public's health." A research scientist from a major pharmaceutical company, who parti cipated in the roundtable by speakerphone to protect anonymity, said that "drug companies will not conduct safety studies unless they have to - meaning basically that they're required by a regulator - and that rarely happens."

The industry researcher explained that the studies that are the basis for regulatory approval are too small and are conducted over too brief a period to properly assess safety. There are "blockbuster drugs" out there, said the scientist, that "might be associated with tens of thousands of deaths a year" but this risk "would never be detected in studies of the kind that we routinely submit and are the basis for approval. These drugs are essentially out there now, unlabeled, unnoticed, all beneath the radar."

Lenzer's account captures some of the ways in which industry may influence not only which drugs get approved, but also which drugs get prescribed.

One of the roundtable whistleblowers was Allen Jones, a former investigator at the Pennsylvania Office of the Inspector General, who filed a civil rights lawsuit on November 22 2002 "to preserve my job and my right to speak out."

Jones explained that he had investigated an account into which pharmaceutical companies were paying money that was being accessed by state officials. These officials "were given unrestricted educational grants that were deposited into an off-the-books account - unregistered, unmonitored, literally operated out of a drawer." The officials, he said, were responsible for writing guidelines for the treatment of patients in the state system and were receiving money from companies with a stake in these guidelines.

The marketing tactics used by drug companies came under scrutiny at the roundtable. Kathleen Slattery-Moschkau, a former drug representative who wrote and directed the movie Side Effects, a fictionalized account of her experiences, explained how companies bought doctors' prescribing records so drug representatives knew "to the dime" what drugs doctors were prescribing and could tailor their marketing to them.

Lenzer concludes in her account that each of these whistleblowers, in very different ways - from making a satiric film to speaking out in Congress - has shone light on how the "synchrony" between the pharmaceutical industry and the medical enterprise may be compromising the integrity of American medicine. "We should not have to rely on medical whistleblowers to alert us to these fault lines," she says. "If we are to restore objectivity to drug development, prescribing, and safety monitoring, we must be willing to examine and change all of the institutions that allow this synchrony to occur."

In a related editorial, the PLoS Medicine editors explain why PLoS sponsored the roundtable and why they published Lenzer's account: "Lenzer's report will, we hope, spark discussion and debate about how American medicine - clinicians, researchers, regulatory agencies, and medical journals - can disentangle itself from the influence of the pharmaceutical industry."


Source:PLoS Medecine

Related biology news :

1. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
2. Medical molecules designed to respond to visible light that can penetrate tissue
3. Medical experts: US unlikely to have enough vaccines to stop avian flu
4. Warbling whales speak a language all their own
5. First study to show how immune cells speak to each other in vivo
Post Your Comments:

(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, the ... pharmaceutical innovations, today announced it has signed ... Fund (KDDF) to foster collaboration between KDDF and HUYA ... commercialization of healthcare products for the global market. ... important source of new innovative preclinical and clinical stage ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 BrainStorm ... developer of adult stem cell technologies for neurodegenerative diseases, today ... been awarded an additional grant of approximately $735,000 from ... This grant, the second this year, brings the total awarded ... million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
Breaking Biology Technology: